December 21, 2018 / 6:40 AM / a month ago

BRIEF-Novartis AG Receives Expanded Kisqali Approval In Europe

Dec 21 (Reuters) - Novartis AG:

* SAYS RECEIVES EUROPEAN COMMISSION (EC) APPROVAL FOR EXPANDED INDICATION FOR KISQALI® (RIBOCICLIB)

* SAYS KISQALI HAS EU APPROVAL FOR WOMEN WITH HR+/HER2- LOCALLY ADVANCED OR METASTATIC BREAST CANCER IN COMBINATION WITH FULVESTRANT AS INITIAL THERAPY AND IN WOMEN WHO HAVE RECEIVED PRIOR ENDOCRINE THERAPY Source text for Eikon: Further company coverage: (Reporting by John Miller)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below